Physician profile
Brad Wayne Lebert
NPI 1720278385
$6,736.36
in general payments reported to CMS, 2019-2025
24 companies · $915 in 2025
The $915 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $1,448 · 2021: $312 · 2022: $835 · 2023: $1,912 · 2024: $665 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471 · Travel and Lodging: $794 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.96 |
| Travel and Lodging | $793.64 |
| Education | $227.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $1,752.41 | 2019-2024 | Trudi Nav Cable, Spine & Trauma 3d Navigation, Acclarent Navwire |
| Aerin Medical INC. | $1,192.15 | 2019-2025 | |
| Medical Device Business Services, INC. | $1,155.82 | 2020 | |
| Genzyme Corporation | $501.96 | 2019-2025 | |
| Integra Lifesciences Corporation | $497.78 | 2024-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Optinose US, INC. | $477.15 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $316.00 | 2022-2025 | Dupixent |
| Kaleo, INC. | $134.39 | 2019-2021 | |
| Stryker Corporation | $125.60 | 2019-2021 | |
| Glaxosmithkline, LLC. | $122.24 | 2023-2025 | Nucala, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $109.98 | 2023-2025 | |
| Ethicon US, LLC | $57.82 | 2019 | |
| Neurent Medical Limited | $54.94 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Inspire Medical Systems, INC. | $44.91 | 2025 | Inspire |
| Itamar Medical INC | $39.14 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $35.31 | 2023 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $25.12 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $19.21 | 2025 | Xhance |
| Intersect Ent, INC. | $14.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2024 | Farxiga |
| Cook Medical LLC | $13.58 | 2023 | Biodesign |
| Merck Sharp & Dohme LLC | $12.76 | 2023 | Belsomra |
| Exact Sciences Corporation | $12.70 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $6.84 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Lebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.